Background

The published NHS England guidance on the 2027 NHS Carbon Reduction Plan requirements for the procurement of NHS goods, services and works marks a significant extension of NHS England’s wider net zero ambition and supplier roadmap. It moves beyond the earlier UK-focused Carbon Reduction Plan model by requiring suppliers to report relevant global Scope 1, 2 and 3 emissions and publish a strengthened carbon reduction plan from April 2027. In September 2025, BIVDA undertook a programme of member engagement to ensure industry concerns were clearly reflected in the response to NHS England’s 2025 market sounding on the draft technical approach. This included gathering and aligning feedback from Members on the feasibility of global emissions reporting, the burden of full Scope 3 disclosure, the practical challenges of applying uniform requirements across complex international supply chains, and the risk that disproportionate procurement thresholds could create barriers to participation. BIVDA then consolidated this evidence into a coordinated response to ensure that member views on proportionality, deliverability and market impact were clearly represented in discussions with NHS England.

Overall position

The published guidance reflects some elements of the feedback BIVDA provided in September 2025, but it does not resolve the central concerns raised by industry about feasibility, proportionality and alignment with existing government requirements. For the IVD sector, the most significant issue remains that the guidance requires a broader and more complex reporting approach than current PPN 006 expectations, particularly through the adoption of global emissions boundaries and expanded Scope 3 reporting.

Where the guidance has responded to BIVDA feedback

The guidance has moved on the net zero target date. In its consultation response, BIVDA argued that the NHS should align with the wider UK and global 2050 target rather than require 2045. The guidance now states that suppliers must commit to net zero by 2050 or earlier, rather than making 2045 the compliance requirement, although a 2045 target remains an NHS ambition.

The guidance also acknowledges that suppliers may not have access to complete supply chain data and may need to use estimation methods, including spend-based approaches, to calculate Scope 3 emissions. This reflects BIVDA’s concern that many suppliers would struggle to obtain robust data across complex global supply chains.

In addition, the guidance introduces a tiered approach between the 2027 NHS CRP and the 2024 CRP, and includes language on proportionality, exceptional circumstances and support for SMEs and VCSEs. This indicates that NHS England has recognised, at least in part, industry concerns about burden and market access.

Where the guidance does not align with BIVDA feedback

Despite these changes, the most important concerns raised by BIVDA remain largely unresolved. BIVDA made clear that suppliers would struggle to report across all 15 Scope 3 categories and called for closer alignment with the narrower PPN 006 approach. However, the guidance continues to require reporting of all relevant Scope 3 emissions in line with the GHG Protocol for the 2027 NHS CRP.

BIVDA also raised serious concerns about requiring a global reporting boundary, given that many NHS suppliers operate within international organisations and complex global supply chains that are not aligned to UK-specific reporting structures. The guidance nevertheless explicitly requires a global geographical boundary for both net zero commitment and emissions reporting.

BIVDA also asked for alignment with PPN 006 to avoid conflicting or duplicative requirements. However, the guidance goes beyond the 2024 CRP and current PPN 006 model by requiring broader Scope 3 reporting and a global reporting boundary.

BIVDA also highlighted the distortion that can arise when high-value or framework-level requirements are applied to suppliers whose actual contract value may be significantly lower, particularly in managed service arrangements. The guidance confirms that all new frameworks are in scope irrespective of contract value, unless the framework owner decides that the 2027 requirements are not proportionate.

A further significant concern is that the guidance does not provide a clear or workable timetable for the capture and submission of emissions data. If the new requirements are intended to apply from 2027, but the final guidance has only now been published, many suppliers will not have a complete 2026 data set available in time to support submissions in 2027. This is particularly problematic for Scope 3 reporting, where data collection is inherently retrospective, dependent on third parties, and often subject to long internal validation cycles. Without a realistic lead-in period and clear clarification on which reporting year will be accepted for initial compliance, there is a serious risk that suppliers will be judged against requirements they have not had sufficient time to prepare for, despite acting in good faith.

A further concern is that many of the apparent concessions or flexibilities in the guidance are not set as clear, centrally governed rules by NHS England, but instead rely on the judgement of the contracting authority at the point of procurement. In practice, this creates a significant risk of inconsistency across frameworks, tenders and contracting bodies, with suppliers facing different interpretations of proportionality, exemptions and evidential expectations depending on who is running the procurement. This lack of standardised oversight weakens the value of the flexibilities described in the guidance and creates uncertainty for suppliers trying to plan compliance on a consistent basis across the NHS market.

Key challenge:

The principal challenge for the IVD sector is that the guidance increases compliance complexity without providing a sufficiently standardised or practical mechanism for suppliers to meet the requirements consistently. This is particularly acute for IVD suppliers, whose business models often rely on global manufacturing, distribution and subcontracted supply chains operating in an increasingly complex geopolitical and regulatory environment. The guidance does not adequately accommodate the reality of global geopolitical friction, trade disruption and differing international reporting regimes, and instead applies a restrictive procurement policy to areas of the supply chain over which individual suppliers may have limited practical influence or ability to secure binding commitments. The likely consequence is higher compliance costs, variable data quality and a greater risk that otherwise capable suppliers are disadvantaged or excluded from NHS procurement on a pass/fail basis.

 

Summary:

Overall, while the guidance reflects some movement in response to industry feedback, it does not address the fundamental feasibility concerns raised by BIVDA. The main risk for the IVD sector is that the move to global, expanded Scope 3 reporting creates a disproportionate burden for diagnostics suppliers operating in complex international supply chains, potentially acting as a barrier to market participation and reducing supplier diversity.

BIVDA next steps: BIVDA will continue to engage with NHS England to seek clarification on the practical operation of the 2027 requirements, including implementation timescales, evidential expectations and the application of proportionality in framework and contract settings. We will also seek clarity on whether a full impact assessment has been undertaken in relation to the implementation of this guidance, including its potential effects on supplier participation, proportionality and market access. In parallel, we will gather further member intelligence on the likely operational and commercial impact of the guidance across our sector, so that emerging concerns can be evidenced clearly and consistently in ongoing discussions.